81. Lombardi Cancer Center - Clinical Services Winzip application to open. 01201 CYCLOPHOSPHAMIDE AND THALIDOMIDEIN RELAPSED OR REFRACTORY multiple myeloma, Protocol, Protocol. http://lombardi.georgetown.edu/clinicalProtocols/index.cfm?diseaseID=15

82. Multiple Myeloma A variant Burkitttype translocation (8;22)(q24;q11) in multiple myeloma. Volume9, Third Series. AFIP Press. 1994. Commonly Used Terms With multiple myeloma. http://www.thedoctorsdoctor.com/diseases/mulitple_myeloma.htm

Background This is a cancer of the plasma cells, usually beginning in the bone marrow. These neoplastic plasma cells produce immunoglobulins and evolve from B lymphocytes. The disease typically involves the bones and kidneys and may lead to kidney failure. Patients may complain of back pain, weakness, and fatigue. However, rarely patients may be diagnosed during a serum protein electrophoresis. The immunoglobulins which are produced by the plasma cells may be detected in both the blood serum and urine by sophisticated electrophoresis testing. The bone marrow aspiration and biopsy, usually performed by the pathologist, is one of the most important tests that can be performed to establish the diagnosis. If possible, the biopsy should be directed at a site of a lytic bone lesion. The pathologist can use immunohistochemistry upon the tissue sample to identify these abnormal immunoglobulins and establish the diagnosis. OUTLINE Epidemiology Disease Associations Pathogenesis Laboratory/Radiologic/Other Diagnostic Testing ... Internet Links EPIDEMIOLOGY CHARACTERIZATION SYNONYMS Plasma cell myeloma INCIDENCE 3.9/100,000 in USA

83. Multiple Myeloma Overview of multiple myeloma, a cancer of the plasma cells. Related testsCBC, BUN, Creatinine. multiple myeloma is a cancer of the plasma cells. http://www.labtestsonline.org/understanding/conditions/mult_myeloma.html

TESTS test not listed? ACTH AFB Culture AFP Maternal AFP Tumor Marker Albumin Aldosterone Allergies ALP ALT Amylase ANA Antibody Tests Apo A Apo B ApoE Genotyping AST Bilirubin Blood Culture Blood Gases BMP BNP Bone Markers BRCA BUN C-peptide CA-125 CA 15-3 CA 19-9 Calcium Cardiac Risk CBC CEA CF Gene Mutation Chlamydia Chloride Cholesterol CK CK-MB CMP Cortisol Creatinine Creatinine Clearance CRP CRP, high-sensitivity Cystatin C DHEAS Differential EGFR Electrolytes ESR Estrogen Estrogen Receptors Fecal Occult Blood Ferritin Flu Tests FSH Genotypic Resistance GFR GGT Glucose Gonorrhea Gram Stain Growth Hormone hCG HDL Hematocrit Hemoglobin Hepatitis A Hepatitis B Hepatitis C Her-2/neu Herpes HIV Antibody Home Tests Homocysteine HPV H-pylori hs-CRP Insulin Iron Tests LD LDH LDL Lead LH Lipase Lipid Profile Liver Panel Lp(a) Lyme Disease Magnesium Microalbumin Mono Monoclonal Protein Myoglobin Pap Smear Phosphorus Platelets Potassium Prealbumin Progesterone Progest. Receptors Prolactin PSA PT PTH Red Count Renin Rheumatoid Factor Rubella Semen Analysis Serum Iron Sickle Cell Sodium Strep Throat Sweat Chloride Syphilis Tau/Aß42 TB Skin Test Testosterone Ther. Drug Monitoring

84. Multiple Myeloma multiple myeloma multiple myeloma, FBC , blood film ; ESR ; protein(total), albumin; protein electrophoresis, paraprotein typing http://www.rcpa.edu.au/pathman/multipl3.htm

Multiple myeloma Multiple myeloma FBC blood film ESR ; protein (total), albumin; protein electrophoresis, paraprotein typing, immunoglobulins G, A, M to identify and quantitate paraprotein and detect immune paresis. Urine - protein, Bence Jones protein. Bone marrow aspiration and trephine biopsy . Creatinine, urea, calcium, phosphate, electrolytes. Beta-2-microglobulin may be useful to establish tumour load (prognostic significance) and for monitoring. Viscosity - plasma, occasionally useful. Pathological fracture See Bone fracture (pathological) Hypercalcaemia Nephrotic syndrome Renal failure Immunodeficiency Infection (increased susceptibility) Hyperviscosity Bleeding Thrombocytopenia Cytotoxic drugs and/or irradiation Predictable effect. Disease progression Paraprotein effects See Paraproteinaemia Anaemia esp Usually normochromic, normocytic to macrocytic (round macrocytes). Cytotoxic drugs and/or irradiation Disease progression Amyloidosis

85. Short Description Of Cell Lines. Tumor Multiple Myeloma Version 4.200201, Short description of cell lines. Tumor multiplemyeloma. By selecting the cell line name, you will receive the http://www.biotech.ist.unige.it/cldb/tum167.html

86. Multiple Myeloma: What It Is And How It's Treated multiple myeloma What It Is and How It's Treated. What is multiplemyeloma? Where can I get more information about multiple myeloma? http://familydoctor.org/handouts/376.html

Information from Your Family Doctor Multiple Myeloma: What It Is and How It's Treated What is multiple myeloma? Multiple myeloma (say: "my-el-oh-ma") is a kind of cancer in the bone marrow (tissue inside the bones where new blood cells are made). It's caused when your body makes too many of a certain blood cell, called a "plasma cell." When this happens, the abnormal plasma cells group together and form tumors. They kill the bone cells around them and keep other blood cells that you need from being made. Normally, plasma cells help the immune system by making different antibodies called immunoglobulins. Immunoglobulins are proteins in the blood that help to kill bacteria, viruses and other germs that attack your body. However, in people with myeloma, the plasma cells don't make the right kind of immunoglobulins to fight infections. Instead they make too much of one kind of immunoglobulin that can cause problems. What causes myeloma? We don't know what causes myeloma. This cancer usually happens in people older than 55 years of age. It is slightly more common in men than in women. It doesn't usually run in families. Myeloma is more common in blacks than in whites. Some studies suggest that workers in agriculture or petroleum-based industries may be at greater risk. How does my doctor know if I have myeloma?

87. Multiple Myeloma next up previous Next Case 1 Up Atlas of HematologyPrevious Case 3. multiple myeloma. http://pathy.med.nagoya-u.ac.jp/atlas/doc/node78.html

88. Conditions And Illnesses Q&A - Multiple Myeloma multiple myeloma. Questions and Answers About multiple myeloma. 1. What ismultiple myeloma? 4. What are some of the symptoms of multiple myeloma? http://www.uams.edu/medcenter/conditions/myeloma.asp

Acne Aortic Aneurysm Breast Cancer Cosmetic Surgery ... Weight Control Select a Condition or Illness Acne Aortic Aneurysm Breast Cancer Cosmetic Surgery Diabetes Epilepsy Heart Disease Heart Failure Multiple Myeloma Pregnancy Prostate Cancer Travel Medicine Weight Control MULTIPLE MYELOMA Questions and Answers About Multiple Myeloma 1. What is multiple myeloma? 2. Why are plasma cells important? 3. What happens to affected plasma cells? 4. What are some of the symptoms of multiple myeloma? ... 11. What can a patient expect from the Myeloma Institute's patient care team? Making an Appointment at UAMS Medical Center To make an appointment, call 1-501-686-8000 or 1-800-942-8267. 1. What is multiple myeloma? Multiple myeloma is a type of cancer that affects plasma cells, which are a type of white blood cell. Plasma cells and other white blood cells are part of the immune system, which helps the body protect itself from infection and disease. All white blood cells develop in the bone marrow, the spongy tissue that fills the centers of most bones. Some of these white blood cells remain in the bone marrow, and some migrate to other parts of the body. Some of the white blood cells, whether in the marrow or other parts of the body, develop into plasma cells when the immune system needs them to fight infection and disease. 2. Why are plasma cells important?

89. Diseases And Conditions -- Discovery Health -- Multiple Myeloma multiple myeloma occurs when a specialized white cell, known as a plasma cell,becomes cancerous. multiple myeloma By Miriam P. Rogers, EdD, RN, AOCN, CNS. http://health.discovery.com/diseasesandcond/encyclopedia/2555.html

multiple myeloma By Miriam P. Rogers, EdD, RN, AOCN, CNS Multiple myeloma occurs when a specialized white cell, known as a plasma cell, becomes cancerous. What is going on in the body? Like all components of blood, plasma cells are produced in the bone marrow. Plasma cells produce proteins that help protect the body from infection. After one or more of these cells becomes cancerous, they multiply rapidly. The proteins these cancerous cells make do not work as well as normal proteins. The cancerous cells produce very large amounts of the faulty proteins. These cancerous cells may also crowd out normal cells. Some of the cancerous plasma cells will leave the bone marrow and enter the bloodstream. Some of these cells may enter bones and destroy them. The disease usually takes many years to develop. What are the signs and symptoms of the disease? A person with multiple myeloma may not have any symptoms early in the disease. Some individuals do notice problems, including: pain, which occurs when the bones are affected. The bones may be so weak that they break easily. frequent infections, which may cause illness for some time before the cancer is diagnosed

90. Exploring Cancer Type - Hematological - Multiple Myeloma multiple myeloma. External Links You National Cancer Institute (NCI) •What You Need to Know About™ multiple myeloma. NCI/PDQ® Multiple http://www.cancer.mgh.harvard.edu/resources/cancer_crr_cancertypeHEMMALMYELOMA.h

Home Learn About Cancer Contact Us Site Map Information Finder Lists Books, Videos, and Websites ... Glossary Types of Hematological Cancers: Hodgkin's Disease Multiple Myeloma Leukemia Other Hematological Cancers Lymphoma Multiple Myeloma National Cancer Institute (NCI) Treatment Patient - Consumer level Health Professional Treatment Patient - Consumer level Health Professional American Society of Clinical Oncology (ASCO) Choose a Diagnosis Adrenal Tumors AIDS-Related Amyloidosis Anal Cancer Anemia Aplastic Anemia Bile Duct Cancer Bladder Cancer Brain Tumor, Adult Breast Cancer Carcinoid Tumor Cervical Cancer Childhood Cancers Clotting Disorders Colon Cancer Endometrial Cancer Esophageal Cancer Gallbladder Cancer Gastric Cancer Gastroesophageal Cancer Gastrointestinal Cancer Gaucher's Disease Head and Neck Cancer Hematology Hepatic Carcinoma Hepatic Metastises Immunodeficiency Intestinal Cancer Laryngeal Cancer Leukemia Leukopenia Liver Cancer Lung Cancer Lymphoma Melanoma Mesothelioma Molar Pregnancy Multiple Myeloma Musculoskeletal Tumors Mycosis Fungoides Myelodysplasia Nasopharyngeal Cancer Neuroblastoma Neurologic Tumors Ovarian Cancer

91. U-M CCC - Information Guide - Multiple Myeloma Updated 3/2003. multiple myeloma Information Guide. The purpose of Myelomamultiple myeloma Research Foundation. multiple myeloma A http://www.cancer.med.umich.edu/learn/pwmyeloma.htm

Patient Education Resource Center Print-friendly version of this guide Show me other Information Guides (also known as PERC Pathways) Updated 3/2003 Multiple Myeloma Information Guide The purpose of this information guide is to help patients newly diagnosed with Multiple Myeloma find sources of information and support. This list is not meant to be comprehensive, but rather to provide starting points for information seeking. The materials can be found at the Patient Education Resource Center of the University of Michigan Comprehensive Cancer Center in room B1-361. Pamphlets - Available in the Patient Education Resource Center on Level B-1 Myeloma Multiple Myeloma Research Foundation. Multiple Myeloma: A Disease Overview (Note: You need Adobe Acrobat Reader to open the above link). Multiple Myeloma Research Foundation. Current and Emerging Trends in the Treatment of Multiple Myeloma (Note: You need Adobe Acrobat Reader to open the above link).

92. ScienceDaily News Release: Thalidomide Therapy For Multiple Myeloma Patients May Nearly onethird of patients with advanced multiple myeloma who had failed currentstandard therapy of chemotherapy or stem cell transplantation responded to http://www.sciencedaily.com/releases/2003/01/030114072052.htm

Search Our Archives Keywords: Order by: date relevance More options Get ad-free access with email updates sign up or log in Text size: A A A Welcome Home page About this site Awards, reviews News Summaries Headlines Topics Shop Our stuff Browse books Magazines Software Contribute Register free Post release Edit profile Review hits Advertise Media kit Traffic stats Contact us Previous Story ... Related Stories Next Story Source: Mayo Clinic Date: Thalidomide Therapy For Multiple Myeloma Patients May Lengthen Survival, Researchers Report ROCHESTER, Minn. Nearly one-third of patients with advanced multiple myeloma who had failed current standard therapy of chemotherapy or stem cell transplantation responded to thalidomide for a median duration of nearly one year in a Mayo Clinic study of the effects of thalidomide on myeloma. The findings are reported in the January issue of Mayo Clinic Proceedings. Many studies in the last three years have determined that thalidomide is effective in the treatment of multiple myeloma, following the initial report by researchers at the University of Arkansas. However, information is limited on how long thalidomide therapy works and on survival rates with such therapy. The Mayo Clinic researchers report on the results of a study that looked at 32 patients with relapsed multiple myeloma. "Thalidomide is useful in the treatment of patients with relapsed multiple myeloma," said Vincent Rajkumar, M.D., a hematologist at Mayo Clinic and an author of the study. "Our study confirms an earlier report from the University of Arkansas that among patients who respond to therapy, the benefits are not transient, but last approximately one year on average." Studies are now addressing thalidomide's role in combination with other treatments and in earlier stages of the disease.

93. Disease Category Listing (212): Multiple Myelomas of Hope National Medical Center An International, NonComparative, Open-Label Studyof PS-341 Administered to Patients with multiple myeloma Who Experienced http://www.centerwatch.com/patient/studies/cat212.html

Clinical Trials: Multiple Myelomas California Duarte; City of Hope National Medical Center An International, Non-Comparative, Open-Label Study of PS-341 Administered to Patients with Multiple Myeloma Who Experienced Relapsed or Progressive Disease after Receiving at Least Four Previous Treatment Regimens or Experienced Progressive Disease after Receiving Dexamethasone in Millennium Protocol M34101-039 Duarte; City of Hope National Medical Center An International, Multi-Center, Randomized, Open-Label Study of PS-341 Versus High-Dose Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma Duarte; City of Hope National Medical Center Sequential High-Dose Melphalan and Busulfan/Cyclophosphamide Followed by Peripheral Blood Progenitor Cell Rescue, Interferon, Pamidronate, with or without Thalidomide, for Patients with Multiple Myeloma Duarte; City of Hope National Medical Center Phase II Randomized Trial of Bevacizumab Versus Bevacizumab and Thalidomide for Relapsed/Refractory Multiple Myeloma Duarte; City of Hope National Medical Center

94. 1Up Health > Multiple Myeloma > Causes, Incidence, And Risk Factors Of Multiple Comprehesive information on multiple myeloma (Malignant plasmacytoma,Plasma cell dyscrasia, Plasma cell myeloma, Plasmacytoma of bone). http://www.1uphealth.com/health/multiple_myeloma_info.html

1Up Health Multiple myeloma Alternative Medicine Clinical Trials ... Health Topics A-Z Search 1Up Health Multiple myeloma Information Multiple myeloma Causes, Incidence, and Risk Factors Alternative names : Malignant plasmacytoma, Plasma cell dyscrasia, Plasma cell myeloma, Plasmacytoma of bone Definition : Multiple myeloma is a cancer of the plasma cells in bone marrow. Causes, Incidence, and Risk Factors Multiple myeloma is characterized by the excessive growth and malfunction of plasma cells in the bone marrow. The growth of these extra plasma cells interferes with the production of red blood cells, white blood cells, and platelets . This causes anemia , susceptibility to infection, and increased tendencies toward bleeding. As the cancer cells grow and expand in the bone marrow, they also cause pain and destruction of the bones. If the bones in the spine are affected, compression of the nerves may result causing numbness or paralysis Renal failure (kidney failure) is a frequent complication caused by excess calcium in the blood that results from bone destruction. Multiple myeloma mainly affects older adults. Other risk factors are unknown. This disease is rare and only 3 new cases per 100,000 people per year occur. Previous Next Jump to Another Section of this Guide Definition Causes, Incidence, and Risk Factors

95. Multiple Myeloma : A Survivor's Experiences multiple myeloma. I was diagnosed with multiple myeloma in 1993 by Dr. CocciaPortugal.It was under control until my relapse in April 1995. http://newtianxian.com/english/cured/multiple_myeloma/index.shtml

MULTIPLE MYELOMA University of the North P B X1106 SOVENGA 0727 Northern Province SOUTH AFRICA 6 August 1997 Dear Sir Thank you for your faxed response dated 15/7/97. In my fax I had requested confirmation on the dosage (New Tian Xian China No. 1) for prevention. Mandy Theng confirmed that I need only take 10cc a day at 09h00. Last week I received a booklet, sent by my brother, titled "One Hundred Questions to China No. 1 Tian Xian Liquid". I quote from this booklet, question no.43 page 07: "Is it necessary to take China No.1 Tian Xian Liquid for a whole life? Generally the dose applications are divided into 3 stages: In the case of combined application with surgery and chemotherapy, please insist on the dosage for 3 to 6 months (with suspension of about 5 days between each month) until confirmation of hospital examination that the tumour shall have diminished or disappeared. Owing to the high relapse rate of as much as 60% within 5 years of the cancer disease, dosage should be taken for one month in March and September during the three subsequent years." Please can you clear my confusion regarding the above matter.

96. Multiple Myeloma multiple myeloma up. Related topics multiple myeloma, One in a series ofbooklets about leukaemia and related diseases directed at the public. http://omni.ac.uk/browse/mesh/detail/C0026764L0026764.html

Multiple Myeloma [up] Related topics: broader Paraproteinemias other Ehlers-Danlos Syndrome Telangiectasia, Hereditary Hemorrhagic Waldenstrom Macroglobulinemia International Myeloma Foundation (UK) This organisation provides a diverse range of information, education and support concerning the treatment and management of Myeloma for patients. The services have been developed with the help and support of many of the UK’s leading Myeloma specialists and are designed to help patients make informed decisions about their treatment and care. This Web site is a useful information resource for professionals working with myeloma patients, and also contains a list of publications and links to other relevant organisations. Charities Multiple Myeloma Organizations, Nonprofit Patient Education ... Multiple myeloma One in a series of booklets about leukaemia and related diseases directed at the public. The document covers the causes, signs and symptoms, diagnosis, treatment, and prognosis of multiple myeloma (cancer which affects plasma cells in the bone marrow). Published on the web by the Leukaemia Research Fund. Multiple Myeloma Patient Education Multiple Myeloma A collection of articles on multiple myeloma, from the May/June 1998 issue of Cancer Control, the journal of the Moffitt Cancer Center. Topics covered include biology of the transition of monoclonal gammopathy of undetermined significance to multiple myeloma, management of myeloma, interferon treatment, hematopoietic cell transplantation for multiple myeloma, overview of treatment, imaging in oncology, ten best readings on multiple myeloma and plasma cell dyscrasias, and a list of information for patients. CME accreditation is also available. Published on the Web by the Moffitt Cancer Center.

97. Mayo Clinic - Thalidomide Therapy For Multiple Myeloma Patients May Lengthen Sur Friday, January 10, 2003. Thalidomide Therapy for multiple myeloma Patientsmay Lengthen Survival, Mayo Clinic Researchers Report. ROCHESTER, Minn. http://www.mayoclinic.org/news2003-rst/1609.html

search: Mayo Clinic Locations: Arizona Florida Minnesota Mayo Clinic in Rochester Friday, January 10, 2003 Thalidomide Therapy for Multiple Myeloma Patients may Lengthen Survival, Mayo Clinic Researchers Report ROCHESTER, Minn. Nearly one-third of patients with advanced multiple myeloma who had failed current standard therapy of chemotherapy or stem cell transplantation responded to thalidomide for a median duration of nearly one year in a Mayo Clinic study of the effects of thalidomide on myeloma. The findings are reported in the January issue of Mayo Clinic Proceedings. Many studies in the last three years have determined that thalidomide is effective in the treatment of multiple myeloma, following the initial report by researchers at the University of Arkansas. However, information is limited on how long thalidomide therapy works and on survival rates with such therapy. The Mayo Clinic researchers report on the results of a study that looked at 32 patients with relapsed multiple myeloma. “Thalidomide is useful in the treatment of patients with relapsed multiple myeloma,” said Vincent Rajkumar, M.D., a hematologist at Mayo Clinic and an author of the study. “Our study confirms an earlier report from the University of Arkansas that among patients who respond to therapy, the benefits are not transient, but last approximately one year on average.” Studies are now addressing thalidomide’s role in combination with other treatments and in earlier stages of the disease. The researchers note that an estimated 14,600 new patients were diagnosed with myeloma in the United States during 2002 and an estimated 10,800 deaths will be due to myeloma in the same period. The average survival from diagnosis among patients treated with conventional chemotherapy is three to four years. Multiple myeloma, cancer of the bone marrow, remains an incurable cancer despite advances in high-dose chemotherapy and stem cell transplantation therapy. Thalidomide is not currently approved by the U.S. Food and Drug Administration for the treatment of myeloma.

98. Agent Orange: Multiple Myeloma multiple myeloma multiple myeloma is characterized by proliferationof bone marrow stem cells resulting in an excess of neoplastic http://www.lewispublishing.com/myeloma.htm

Multiple Myeloma Multiple Myeloma is characterized by proliferation of bone marrow stem cells resulting in an excess of neoplastic cells with the production of excess abnormal protein, usually immonoglobulins. Identification of these proteins in the blood or urine represents the best diagnostic feature of this disease. The pelvis, spine, ribs and skull are frequently involved. Persistent unexplained skeletal pain (especially in the back or thorax) renal failure or recurrent bacterial infections, on the most common presenting symptoms. Anemia with weakness and fatigue may predominate in some patients, and few present with manifestations of the hyperviscosity syndrome. Pathologic fractures and vertebral collapse are common; the latter may lead to spinal cord compression and paraplegia. Physical examination usually is not helpful unless bone pain is present. X-Ray of the bones may show the typical punched-out lytic lesions or a diffuse osteoporosis. The bone marrow usually contains increased numbers of plasma cells at various stages of maturation; rarely, the number of plasma cells is normal. Although sheets and clusters of plasma cells are diagnostic of marrow tumors, myeloma is a patchy disease and often only modest nonspecific plasmacytosis is observed. Return to VA Compensation Page

99. BioSpace : CCIS : Search Results For Indication = 'Multiple Myeloma' 35 Search Results for Indication = 'multiple myeloma'. Patients See ClinicalResearch Studies currently enrolling patients for multiple myeloma. http://www.biospace.com/ccis/search.cfm?RXTargetID=230

100. THE MERCK MANUAL, Sec. 11, Ch. 140, Plasma Cell Dyscrasias Macroglobulinemia. multiple myeloma. Heavy Chain Diseases. click here for navigationhelp. multiple myeloma (Plasma Cell Myeloma; Myelomatosis). http://www.merck.com/pubs/mmanual/section11/chapter140/140d.htm

This Publication Is Searchable The Merck Manual of Diagnosis and Therapy Section 11. Hematology And Oncology Chapter 140. Plasma Cell Dyscrasias Topics [General] Monoclonal Gammopathy Of Undetermined Significance Macroglobulinemia Multiple Myeloma ... Heavy Chain Diseases Multiple Myeloma (Plasma Cell Myeloma; Myelomatosis) A progressive neoplastic disease characterized by marrow plasmacytomas (plasma cell tumors) and overproduction of an intact monoclonal immunoglobulin (IgG, IgA, IgD, or IgE) or Bence Jones protein (free monoclonal or light chains). Etiology and Pathogenesis The etiology is unknown. A relationship is suggested by finding Kaposi's sarcoma-associated herpes virus in the dendritic cells cultured from myeloma patients. This virus encodes an interleukin-6 homologue; human interleukin-6 promotes myeloma growth and stimulates resorption of bone. The specific cell of origin is unknown. Analysis of immunoglobulin gene sequences and cell surface markers suggests malignant transformation of a post-germinal center cell. Pathology Diffuse osteoporosis or discrete osteolytic lesions develop, usually in the pelvis, spine, ribs, and skull. Lesions are due to bone replacement by expanding plasmacytomas or a factor secreted by malignant plasma cells (osteoclast-activating factor). The osteolytic lesions are usually multiple but occasionally are solitary intramedullary masses. Extraosseous plasmacytomas are unusual but may occur in any organ, especially the upper respiratory tract.

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

Page 5     81-100 of 111    Back | 1  | 2  | 3  | 4  | 5  | 6  | Next 20